Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Real Housewives of New Jersey” star Jennifer Fessler didn’t follow her doctor’s advice when she started taking a GLP-1 weight ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Rybelsus (semaglutide) is an oral medication used in combination with exercise and a healthy diet to help treat type 2 diabetes. It’s best taken on an empty stomach but isn’t known to interact ...

Rybelsus (semaglutide) and Ozempic (semaglutide) are prescription drugs used to treat type 2 diabetes. Rybelsus comes as an oral tablet, while Ozempic comes as an injectable liquid solution.

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.

Riding on a surge in global demand for its patented obesity and diabetes medicines Ozempic, Wegovy and Rybelsus, ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1.